Coming Soon
About Cynaptec
Pharmaceuticals
Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders Cynaptec’s initial development program is focused on the use of its proprietary Conjugated Psilocin™ compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders.
Conjugated Psilocinâ„¢ is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.
Press Releases
​
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated PsilocinTM
VANCOUVER, B.C. -- Lobe Sciences Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF), (FWB: LOBE.F) announced today a non-brokered private placement of preferred shares in the capital of Lobe Sciences’ newly created subsidiary Cynaptec Pharmaceuticals, Inc. (“Cynaptec”) for an initial gross proceeds of US$6,000,000 with an exclusive option to purchase additional preferred shares. The total gross proceeds, if the option is fully exercised, would total US$26,000,000.